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The mechanistic basis of liver metastasis in colorectal cancer remains poorly understood. 30 
We previously reported that the sclerostin domain containing-1 (SOSTDC1) protein is 31 
overexpressed in the secretome of metastatic colorectal cancer cells and can inhibit liver 32 
homing. Here, we investigated the mechanisms of SOSTDC1 for promoting invasiveness 33 
and progression of colorectal cancer liver metastasis. SOSTDC1 inhibition of BMP4 34 
maintains the expression of cancer stem cell traits, including SOX2 and NANOG. 35 
Immunoprecipitation and mass spectrometry analyses reveal the association of SOSTDC1 36 
with ALCAM/CD166, which was confirmed by confocal microscopy and competition 37 
ELISA. Interaction with ALCAM is mediated by the N-terminal region of SOSTDC1, 38 
which contains a sequence similar to the ALCAM-binding motif used by CD6.  Knocking 39 
down either SOSTDC1 or ALCAM expression, or using blocking antibodies, reduces the 40 
invasive activity by inhibiting Src and PI3K/AKT signaling pathways.  In addition, 41 
ALCAM interacts with the α2ß1 and α1ß1 integrins, providing a possible link to Src 42 
activation. Finally, inoculation of SOSTDC1-silenced metastatic cells increases mouse 43 
survival by inhibiting liver metastasis. In conclusion, SOSTDC1 promotes invasion and 44 
liver metastasis in colorectal cancer, by overcoming BMP4-specific anti-metastatic signals 45 
and inducing ALCAM-mediated Src and PI3K/AKT activation.   These experiments 46 
underscore the potential of SOSTDC1 as a therapeutic target in metastatic colorectal 47 




Metastasis is a complex process that involves several steps, from extravasation to 50 
colonization at new organs, and requires the coordinated action of a large number of 51 
proteins to modulate different effects on adhesion, migration, invasiveness, and survival in 52 
the target organ 1. Increasing evidence suggests that cancer metastasis is promoted by a 53 
small number of cancer stem cells (CSCs) that undergo self-renewal and differentiation to 54 
promote tumor growth 2. Only CSCs can reinitiate tumor growth after reaching the target 55 
organs 3.  Recently, we have used the KM12 colorectal cancer cell model to analyze which 56 
proteins are relevant in metastasis 4. KM12SM and KM12L4 are highly metastatic 57 
colorectal cancer cells that exhibit features of CSCs as they overexpress CSC markers, (e.g. 58 
CD44, CD133, and EPCAM), as compared to non-metastatic KM12C cells 5, 6. Using 59 
proteomic analysis, we found increased expression levels of SOSTDC1 (sclerostin domain–60 
containing-1, a.k.a. USAG1 or ectodin), EFNA3, and CD137L in the secretome of 61 
KM12SM cells, providing three promising candidates for dissecting the mechanisms of 62 
metastatic colonization 7. However, SOSTDC1 was the only secreted protein and the less 63 
characterized in metastatic dissemination among the three candidates.  In addition, 64 
SOSTDC1 stimulated the migration, invasive ability and liver homing capacity of 65 
colorectal cancer metastatic cells, but did not promote proliferation or primary tumor 66 
growth 7.  67 
SOSTDC1 belongs to the DAN (differential screening-selected gene aberrant in 68 
neuroblastoma) protein family, which also includes SOST, Gremlin-1, Coco, and Cerberus-69 
1 (among others). These proteins inhibit the bone morphogenetic proteins (BMPs) of the 70 
TGFβ family 8, 9. SOSTDC1 is a secreted protein with a glycosylated N-terminus that 71 
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contains a C-terminal cysteine knot (CTCK) domain 10. Of note, this domain is present in 72 
numerous growth factors, including TGFβ, NGF, PDGF, vWF, NDP, and mucin-2, and is 73 
involved in dimerization, receptor binding, and signal transduction. SOSTDC1 negatively 74 
regulates BMP signaling during cellular proliferation, differentiation, and apoptosis in 75 
several biological processes (such as dentary morphogenesis, embryo implantation in the 76 
endometrium, and healing of bone fractures) 8. In addition, SOSTDC1, and its orthologue 77 
Wise, modulate various processes, in development as well as in cancer, through the 78 
regulation of the Wnt pathway 8, 11.   79 
SOSTDC1 expression has been shown to be reduced in primary tumors of renal 12, 80 
breast 13, prostate cancer 14, and non-small cell lung cancer 15 as compared to normal tissue. 81 
However, none of these studies explored differences of SOSTDC1 expression between 82 
metastatic and primary tumors, and only a few reports described SOSTDC1 expression in 83 
metastatic cells16, 17. A critical step in organ colonization during metastasis is to subvert the 84 
cellular programs that impose a state of dormancy on the metastatic cells in the receptor 85 
organ, which is usually imposed by BMPs or other members of the TGFβ pathway.  The 86 
BMP antagonists Coco and Gremlin1 act as a counterbalance for BMP signaling in breast 87 
cancer and glioblastoma, respectively, enabling maintenance of CSCs and reactivating 88 
metastatic colonization or invasive growth 18, 19. However, the effects of SOSTDC1 in 89 
regulation of liver metastasis are totally unknown, and further clarifications, beyond its 90 
capacity of inhibiting BMP4, are necessary.  We should also take into account that late-91 
stage colorectal cancer-derived cell lines display mutational inactivation of the TGF-β 92 
pathway, and that KM12SM and L4 cells carry biallelic TGFBR2 loss-of-function 93 
mutations and do not respond to TGF-β 20, which may affect BMP signaling.  94 
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Here, we have characterized the mechanisms of action of SOSTDC1 in colorectal 95 
cancer cells and how they impact metastasis. Notably, we observed the capacity of 96 
SOSTDC1 to work as a novel ligand of ALCAM to promote invasion and facilitate liver 97 
metastasis in colorectal cancer through activation of the Src-PI3K/AKT pathways. Our 98 




SOSTDC1 is overexpressed in late stages of colorectal cancer 101 
We first examined the expression of SOSTDC1 in eight colon cancer cell lines. Metastatic 102 
cell lines expressed SOSTDC1in cell lysates, and to a greater extent in the conditioned 103 
media, in its secreted form (Fig. 1A). To study its clinical value, we checked SOSTDC1 104 
expression in tumor and adjacent healthy tissue in colon cancer patients as well as in paired 105 
normal and metastatic liver samples.  Normal colon tissue exhibited higher levels of 106 
SOSTDC1 expression than primary tumors. However, the highest expression was found in 107 
metastatic tissues (Fig. 1B). By immunohistochemistry, SOSTDC1 expression in liver 108 
metastasis was significantly higher than in primary tumors (Fig. 1C). This indicates that 109 
SOSTDC1 expression declined in early stages of colorectal cancer, but increased in liver 110 
metastasis, underscoring the potential clinical value of determining its expression levels.  111 
SOSTDC1 promotes cell invasion through the Src, PI3K/AKT, and JNK pathways 112 
Next, we explored the contribution of SOSTDC1 to the invasive properties of SW620, 113 
KM12SM, or KM12L4 cells that had been transiently-silenced for SOSTDC1 with two 114 
different siRNAs (for SW620 and KM12SM), or stably silenced with two lentiviruses (for 115 
KM12L4) (Fig. 2A). A clear reduction in the cell invasion capacity through Matrigel was 116 
observed for SOSTDC1-silenced cells (Fig. 2B). A similar inhibition was obtained with a 117 
polyclonal anti-SOSTDC1 (Fig. 2C). To define the molecular underpinnings of SOSTDC1, 118 
we investigated its capacity to activate the Src and PI3K/AKT pathways in the cell lysates 119 
of metastatic cells. All three cell lines showed a significant decrease in the activation of Src 120 
and AKT after SOSTDC1 silencing. Stably-silenced cells exhibited a major decline in the 121 
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activation of all the signaling proteins, including phospho-JNK. However, ERK 122 
phosphorylation was not reduced in SW620 cells, and an effect on JNK activation was 123 
observed only in KM12L4 cells (Fig. 2D). To confirm the signaling pathways involved in 124 
SOSTDC1-mediated invasion we tested different inhibitors in SW620, KM12SM and 125 
SOSTDC1-silenced or scrambled KM12L4 (Fig. 2E). The increased invasion induced by 126 
SOSTDC1 was strongly reduced by inhibitors of Src (PP2) or PI3K (LY294002). In 127 
agreement with the observed JNK activation, invasion was partially reduced by JNK 128 
inhibitor II in KM12L4 cells, but not in KM12SM or SW620 cells.  In the three cell lines, 129 
invasion was not affected by UO126 (a MEK1/2 inhibitor). Together, these findings 130 
confirm that SOSTDC1-regulated invasion was mediated by the Src and PI3K/AKT 131 
pathways.  132 
SOSTDC1 inhibits BMP4 to maintain expression of stem cell transcription factors 133 
Next, we explored the effects of BMP4 on the SOSTDC1-mediated invasive capacity. 134 
SOSTDC1-silenced or scrambled KM12L4 cells treated with SOSTDC1 (10 ng/mL) 135 
showed a clear increase in their invasive capacity, which was inhibited by BMP4 addition, 136 
in a dose-dependent manner (Fig. 3A). To define the capacity of SOSTDC1 to regulate 137 
BMP signaling in colorectal cancer metastatic cells, we characterized the expression of 138 
BMP receptors and the activation status of the downstream target SMAD5. Both receptor 139 
subunits (BMPR-IB and BMPR-II) were expressed in KM12SM cells, only BMPR-II in 140 
KM12L4 cells, and neither in SW620 cells (Fig. 3B);  thus, as a functional BMP receptor 141 
requires a heterodimer of receptor types I and II, only KM12SM were expected to respond 142 
to BMPs.  To assess BMP signaling, cells were silenced for SOSTDC1 and exposed to 143 
increasing concentrations of BMP4. BMP4 increased pSMAD5 only in KM12SM cells (but 144 
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not in KM12L4 or SW620), and only when high amounts of BMP4 (50-250 ng/mL) were 145 
used in SOSTDC1-silenced cells (Fig. 3B).  Thus, endogenous SOSTDC1 expression was 146 
sufficient to block the effects of BMP4. Of note, stably SOSTDC1-silenced KM12L4 cells 147 
had less pSMAD5 than control transfectants.  148 
We next examined the capacity of SOSTDC1 to promote tumor sphere formation 149 
and to sustain expression of stem cell transcription factors. Neither treatment with 150 
SOSTDC1, or its inhibition with BMP4 altered the colony formation capacity (Fig. 3C). In 151 
contrast, SOSTDC1-silenced KM12L4 cells or KM12SM cells treated with BMP4, showed 152 
significantly inhibited the expression of the pluripotent-associated transcription factors, 153 
such as SOX2, NANOG, EPCAM, BMI1, and ABCF1 (Fig. 3D). OCT4 was undetectable. 154 
Collectively, these results indicated that i) SOSTDC1 and BMP4 have antagonistic actions 155 
in metastasis and ii) the capacity of SOSTDC1 to maintain the pluripotent status of 156 
colorectal CSCs avoiding the inhibitory effect of BMP4.  157 
SOSTDC1 interacts with ALCAM via a CD6-like motif 158 
Beyond its interaction with BMP4, SOSTDC1 is likely to interact with other proteins to 159 
regulate invasion. Therefore, we investigated the SOSTDC1 protein interaction network by 160 
immunoprecipitation followed by mass spectrometry. Cell lysates from metastatic SW620 161 
cells were immunoprecipitated with anti-SOSTDC1, or an irrelevant antibody as a negative 162 
control. After removing ribosomal and proteasomal proteins, we identified 21 proteins 163 
likely to specifically interact with SOSTDC1 (Supplementary Table S1). Among the 164 
interacting proteins, we identified ALCAM, CEACAM5, talin-2, and PI3K-related 165 
proteins, as well as secreted proteins, such as the serpins B6 and B12 (Fig. 4A). With 166 
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respect to its molecular function, some of the interacting proteins were involved in cell 167 
adhesion, migration, and invasion (NHERF1, ARPC4, and PAFAH1B1) and in the PI3K 168 
and Rho-GTPase signaling pathways. The association with CEACAM5, ALCAM, AKT, 169 
BMP4, mTOR, NHERF1, and RAC1 was verified by immunoprecipitation and Western 170 
blot in SW620 and KM12SM cells (Fig. 4B).  171 
Functionally, SOSTDC1-interacting proteins included cell-cell adhesion molecules 172 
(i.e. CEACAM5, ALCAM), secreted proteins and proteins related with the cytoskeleton, 173 
actin polymerization, or microtubules activities. Apart from intracellular proteins, we 174 
excluded CEACAM5 from further analysis due to very limited information about 175 
CEACAM5 interactions. ALCAM is a cell adhesion molecule associated with stemness, 176 
cancer progression, and poor prognosis in colorectal cancer 21, 22. Therefore, ALCAM might 177 
be the link between SOSTDC1 and the cytoskeleton interacting proteins.  ALCAM and its 178 
canonical ligand CD6 22 play a role in the immunological synapsis.  Notably, we identified 179 
motifs similar to CD6 binding sequences in the N-terminal sequence of SOSTDC1 (Fig. 180 
4C). We therefore built an in silico model of SOSTDC1 based not only on its paralog 181 
SOST but also the PEP-FOLD 3 program for its N-terminal region, due to the low 182 
homology (<50%) between SOSTDC1 and SOST in such region. The in silico model 183 
predicted that the three SOSTDC1 sequences similar to those used for CD6 binding to 184 
ALCAM 22 are in close proximity after protein folding, even though two are located in the 185 
N-terminal region and one in loop 1 (Fig. 4D).  Confocal microscopy showed significant 186 
co-localization of both proteins in membrane staining pattern (of 77.1%) (Fig. 4E).  187 
Indirect ELISA revealed that soluble SOSTDC1 can bind coated ALCAM in a dose-188 
dependent manner (Supplementary Fig. S1A). Further, the homotypic binding 189 
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ALCAM/ALCAM was inhibited after adding increasing amounts of soluble SOSTDC1 190 
(Supplementary Fig. S1B). Flow cytometry showed that ALCAM siRNA silencing caused 191 
a clear reduction in the level of SOSTDC1 attached to the cell membrane in SW620 and 192 
KM12SM metastatic cell lines (Figs. 4F, 4G). Collectively, these results provide strong 193 
evidence that SOSTDC1 binds ALCAM in metastatic colorectal cancer cells. 194 
Truncation of the SOSTDC1 N-terminus inhibits ALCAM-mediated migration and 195 
invasion  196 
To further demonstrate that the binding of SOSTDC1 to ALCAM is mediated through the 197 
“CD6-like” binding sequence, we prepared an amino-terminally truncated variant of 198 
SOSTDC1 (ΔN67-SOSTDC1), lacking the first 67 residues and two of the three ALCAM 199 
binding sequences (Supplementary Fig S2). In contrast to the wild-type (WT) SOSTDC1, 200 
ΔN67-SOSTDC1 did not bind the cell membrane (Fig. 5A). Moreover, whereas SOSTDC1 201 
was a potent chemoattractant for colon cancer cells invasion, ΔN67-SOSTDC1 failed to 202 
promote cell invasion (Fig. 5B). Cell migration and invasion are initiated by the formation 203 
of protrusive structures (e.g., filopodia, lamellipodia, or invadopodia) that require 204 
polymerization of actin filaments 23.  The mutant ΔN67-SOSTDC1 did not promote a 205 
significant increase in F-actin content (Fig. 5C). Testing for Src and PI3K activation 206 
pathways in the metastatic cell lines treated with SOSTDC1 or ΔN67-SOSTDC1 revealed a 207 
fast increase (5 min) in Src, AKT, and ERK phosphorylation (and thus pathways) in all cell 208 
lines treated with SOSTDC1, including JNK phosphorylation in KM12L4-stably silenced 209 
cell, while no increase was observed with ΔN67-SOSTDC1 (s (Fig. 5D).  Together, these 210 
results confirm that the N-terminal region of SOSTDC1 is necessary for its binding to 211 
ALCAM, and its ability to promote cell migration and invasion. 212 
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ALCAM regulates cell invasion and actin polymerization in a coordinated way with 213 
SOSTDC1 214 
Knocking down either ALCAM (Fig. 6A) or SOSTDC1 in SW620 or KM12SM cells 215 
drastically reduced the invasive behavior of both cell lines (Fig. 6B, Supplementary Fig. 216 
S3). Moreover, the simultaneous silencing of both proteins did not cause a cumulative 217 
effect in cell invasion, suggesting that both proteins likely use the same mechanisms/ 218 
signaling pathways in invasion. Notably, F-actin content analysis in SW620 or KM12SM 219 
cells silenced for ALCAM or SOSTDC1 revealed that interfering with the expression of 220 
either protein caused a similar, intense reduction in F-actin levels (Fig. 6C). Further, 221 
treating ALCAM-silenced cells with recombinant SOSTDC1 showed no activation of the 222 
Src, AKT and ERK pathways in KM12SM cells (Fig. 6D), demonstrating the dependence 223 
of SOSTDC1 for the ALCAM receptor. ALCAM-ALCAM interactions can activate or not 224 
metalloproteinases to promote cell invasion 24, 25. Here, colorectal cancer cells showed no 225 
differences in the expression and activation of MMP2 and MMP9 after SOSTDC1 226 
silencing (Supplementary Fig. S4), suggesting MMP-independent SOSTDC1-mediated 227 
invasion mechanisms. 228 
To explore the connection between ALCAM and the SRC-PI3K/AKT signaling pathways 229 
we carried out immunoprecipitation of ALCAM. Western blot results indicated the 230 
presence of the α2 and α1 (but not α3) integrins, in the ALCAM immunoprecipitates.  CD9, 231 
a tetraspanin reported to interact with ALCAM, was also present in the interactome (Fig. 232 
6E).  Finally, we investigated the expression of ALCAM in clinical metastatic samples. We 233 
observed a significant association between increased expression levels of ALCAM and 234 
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liver metastasis (Fig. 6F). Together, these results suggest that SOSTDC1 and ALCAM use 235 
identical pathways for promoting invasion and metastasis. 236 
SOSTDC1 expression correlates with ALCAM expression in metastasis, and 237 
SOSTDC1 silencing reduces liver metastasis in mouse models 238 
We next explored the coordinated expression of SOSTDC1 and ALCAM in colorectal 239 
cancer metastasis using a public transcriptomic database with more than 500 patients. After 240 
normalization and calculation of z-scores (Supplementary Fig. S5), we found a significant 241 
correlation between high expression levels of SOSTDC1 or ALCAM and metastasis in 242 
patients (Fig. 7A). Correspondingly, patients with low expression levels showed a lower 243 
presence of metastasis (between 3–6%) than patients with high expression of SOSTDC1 or 244 
ALCAM (12%).  245 
Finally, to investigate the potential therapeutic value of SOSTDC1 in a mouse model of 246 
metastasis, we injected either parental or SOSTDC1-knocked down (KD) KM12L4 cells 247 
into the spleen of Swiss nude mice.  Only one of the mouse inoculated with KD cells died 248 
from metastasis (Fig. 7B). Further, all mice inoculated with parental cells developed 249 
macroscopic liver metastasis, but only one with SOSTDC1-silenced cells developed a 250 
tumor (with a small node in the liver) (Fig. 7C). In addition, we observed a massive 251 
reduction in the liver volume occupied by metastasis in mice inoculated with SOSTDC1-252 
silenced cells (Fig. 7C). Thus, SOSTDC1 is relevant for establishing liver metastasis, 253 




We found that SOSTDC1 is overexpressed in metastatic cell lines and liver metastasis, and 256 
acts as a novel ligand of ALCAM to promote colorectal cancer metastasis. The effects of 257 
SOSTDC1 on invasion and metastasis were mediated by ALCAM as well as the activation 258 
of the Src and PI3K/AKT pathways, likely through the additional interaction of ALCAM 259 
with α2ß1 or α1ß1 integrins (Fig. 7D). Therefore, SOSTDC1 seems to activate a large 260 
protein complex formed by ALCAM, CD9 and ß1 integrins (and perhaps other proteins). 261 
Indeed, knocking down SOSTDC1 in metastatic cells significantly increased mouse 262 
survival and reduced liver metastasis.  263 
 The initial decline of SOSTDC1 expression in colorectal cancer, followed by 264 
expression recovery at late stages, is likely to be epigenetically regulated in a reversible 265 
way, similar to the epithelial-to-mesenchymal transition (EMT)-MET programs that 266 
promote a mesenchymal phenotype at the initial cancer stages followed by a recovery of the 267 
epithelial phenotype at the late stages.  Indeed, the transcriptional regulation of SOSTDC1 268 
was epigenetically regulated in gastric 26, 27 and prostate cancer cells 14. Some reports have 269 
described that reduction of SOSTDC1 in primary tumors is associated with poor outcome 270 
16, 17, 28.  In contrast, we observed that an initial decline in SOSTDC1 expression in the 271 
primary tumors of colorectal cancer had no significant impact on prognostic value.  272 
According to the Human Protein Atlas database 273 
(https://www.proteinatlas.org/ENSG00000171243-SOSTDC1/pathology), SOSTDC1 274 
expression can be associated with a better or worse outcome, depending on the cancer type, 275 
indicating that SOSTDC1´s role in metastasis and its value for prognosis are cancer type-276 
specific. Moreover, in those carcinomas lacking ALCAM (e.g. NSCLC, gastric) both the 277 
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role of SOSTDC1, as well as the molecular mechanisms of migration, invasion and 278 
proliferation are likely to be distinct from those in colorectal cancer.  Indeed, metastatic 279 
colonization by different tumors seems to require organ-specific BMP antagonists: Coco 280 
for lung metastasis in breast cancer 18, Noggin for bone metastasis in prostate cancer 29 and 281 
SOSTDC1 for liver metastasis in colorectal cancer.     282 
Although SOSTDC1 is usually classified as a BMP inhibitor, our evidences now 283 
indicate that SOSTDC1 and BMP4 have antagonistic effects on cancer metastasis. Indeed, 284 
addition of BMP4 inhibited SOSTDC1-promoted colorectal cancer invasion, and 285 
SOSTDC1 inhibited anti-metastatic signals of BMP4. Of note, BMP4 signaling through 286 
SMAD proteins seemed severely impaired in the metastatic cells, except KM12SM, in 287 
which BMP4 promotes SMAD5 phosphorylation only in absence of SOSTDC1. Therefore, 288 
both proteins antagonize each other, inhibiting the binding to their respective receptors.  289 
Likely, in metastatic colorectal cancer, the balance would favor the pro-metastatic effect of 290 
SOSTDC1 over the inhibitory activity of BMP4. We observed a few similarities between 291 
SOSTDC1 in metastatic colorectal cancer cells with the effects of Coco in lung metastasis 292 
in breast cancer cells18: i) SOSTDC1 promotes metastatic colonization without increasing 293 
the proliferation of the primary tumor cells 7, and ii) SOSTDC1 sustains the expression of 294 
stem cell transcription factors, like SOX2 and NANOG 30. In aggressive and metastatic 295 
cancer cells, a reactivation of these transcription factors is required for maintaining the 296 
pluripotent embryonic stem cell phenotype 31. Therefore, SOSTDC1 supports the 297 
reactivation of colon cancer stem cell traits, and thus consequently the capacity for self-298 
renewal and propagation, of the CSCs by inhibiting BMP suppressing effects on NANOG 299 
and SOX2.  300 
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Beyond the inhibition of BMP4, we have demonstrated that SOSTDC1 and 301 
ALCAM associate with each other, and that this association is relevant for invasion and 302 
metastatic progression. These conclusions were based on the following results: i) ALCAM 303 
was immunoprecipitated with SOSTDC1, ii) SOSTDC1 and ALCAM co-localized on the 304 
surface of cancer cells and compete with each other for binding, iii) binding to ALCAM 305 
was mediated through the N-terminal region of SOSTDC1, and iv) silencing of either 306 
SOSTDC1 or ALCAM caused a similar decline in Src and AKT signaling activation, actin 307 
polymerization, and cell invasion. The effects of ALCAM on the Src and AKT signaling 308 
might be explained by the ALCAM association with a cluster of ß1 integrins (including α2 309 
and α1), facilitated by CD9; this would require the triggering of the integrin signaling 310 
pathway and, consequently, Src and PI3K/AKT activation (Fig. 7D).  Notably, the ∆67N 311 
SOSTDC1 mutant inhibited invasion, actin polymerization, and cell signaling mediated by 312 
SOSTDC1 through ALCAM, confirming binding sequences for ALCAM in the N-terminus 313 
of SOSTDC1. Our findings were replicated in three cell lines with different genetic 314 
background. Together these data establish that SOSTDC1 is a ligand for ALCAM, and that 315 
both proteins cooperate in promoting invasion and liver metastasis in colon cancer.  316 
ALCAM, EPCAM and CD44 constitute a robust panel profile for stem cell isolation 317 
from colorectal CSCs 32. In colorectal cancer and other tumors (i.e. melanoma, pancreatic, 318 
mesothelioma), ALCAM expression correlates with a worse prognosis for patients 33-37.  319 
ALCAM associates to the actin cytoskeleton through the ezrin/radixin/moesin (ERM) 320 
family proteins and syntenin-1, which enhances cell motility by binding to the cytosolic tail 321 
of ALCAM 38.  In this regard, our observation that ALCAM associates with CD9 should 322 
facilitate our understanding of the connection with the actin cytoskeleton 39.  Interestingly, 323 
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other proteins present in the SOSTDC1 interactome (such as NHERF1, ARPC4, and 324 
PAFAH1B1) have also been related to actin polymerization, migration, and invasion in 325 
different types of cancer.  Although barely characterized, all share the capacity to promote 326 
actin polymerization and migration. The scaffold protein NHERF1 connects plasma 327 
membrane proteins with members of the ERM family, thereby linking them to the actin 328 
cytoskeleton and regulating their surface expression. ARPC4 (actin-related protein 2/3 329 
complex subunit 4) functions as actin-binding component of the ARP2/3 complex, which is 330 
involved in regulation of actin polymerization. Silencing of ARPC4 significantly reduces 331 
cell migration in pancreatic cancer cell line 40. PAFAH1B1 (platelet-activating factor 332 
acetylhydrolase 1B) is required for proper activation of Rho GTPases and actin 333 
polymerization 41. PAFAH1B1 overexpression contributes to promote migration and 334 
invasiveness of lung cancer cells 42. Another interactor, DRG1, was a component of the 335 
Coco expression signature that predicted overall relapse to the lung 18 and might be another 336 
interesting target to explore in future experiments. Other proteins of the interactome, 337 
including ATXN10, SERPINB12 and SERPINB6 remain to be better characterized for 338 
cancer metastasis. 339 
ALCAM-ALCAM interactions act as a cell density sensor, diapedesis controller, 340 
and as an initiator of a signal that activates metalloproteinases (like MMP-2), all of which 341 
affect the cell invasion capacity 43. Our results indicate that, in colorectal cancer cells, 342 
SOSTDC1 disrupts the ALCAM-ALCAM interaction and promotes the ALCAM-343 
SOSTDC1 interaction relying also on CD9, which strengthens the ALCAM-CD6 344 
interaction in leukocytes 39.  Formation of ALCAM-SOSTDC1 interactions might promote 345 
invasion in colorectal cancer through different mechanisms. Indeed, the effect of ALCAM-346 
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ALCAM interactions in invasion remains controversial. In melanoma, constructs either 347 
lacking the N-terminal domain (ΔN-ALCAM) or a soluble domain 1 of ALCAM 348 
(sALCAM) had positive or negative effects on migration and invasion, respectively, 349 
without activation of MMP2 24, 25. Our results with SOSTDC1 might shed light on this 350 
apparent contradiction.  First, the expression of ΔN-ALCAM would facilitate the 351 
interaction of SOSTDC1 with endogenous ALCAM, promoting migration and invasion. 352 
Second, sALCAM might bind and sequester SOSTDC1, thereby inhibiting both binding of 353 
SOSTDC1 to ALCAM and, consequently, invasion and metastatic capacity 25. In colorectal 354 
cancer cells, SOSTDC1 does not affect the expression of the collagenases, but promotes 355 
cell invasion by disrupting ALCAM homophilic interactions, promoting actin 356 
polymerization and activating the integrin-SRC-PI3K/AKT-ERK signaling pathway.  In 357 
agreement with this, ALCAM depletion leads to a reduced primary tumor size and reduced 358 
metastatic local spread in endometrioid endometrial cancer 44.  ALCAM targeting either 359 
using antibodies that interfere with ALCAM oligomerization or by delivering cytotoxic 360 
payloads have been proposed as therapies for ALCAM positive tumor types 45. Our results 361 
suggest that blocking SOSTDC1 binding to ALCAM (via antibodies, aptamers, or peptides) 362 
might constitute a suitable and valuable strategy for metastasis inhibition.  363 
The identification of SOSTDC1 from a proteomic analysis of the secretome of 364 
metastatic cells demonstrates the value of this type of analysis for identifying relevant 365 
proteins in metastasis. Here, we have elucidated some of the different mechanisms used by 366 
SOSTDC1 to promote invasion and liver metastasis in colorectal cancer. One mechanism 367 
depends on the capacity of SOSTDC1 for sustaining the expression of CSCs transcription 368 
factors, thus maintaining self-replication and stemness status. Another mechanism requires 369 
18 
 
the ability of SOSTDC1 to promote cancer invasion through its interaction with ALCAM. 370 
Our results with shRNA silencing and a commercial anti-SOSTDC1 antibody showed a 371 
clear inhibition of the invasive capacity in metastatic colorectal cancer cells.  Although 372 
further studies are necessary to validate its therapeutic value, SOSTDC1 is likely to be an 373 
interesting target for therapeutic intervention in colorectal cancer metastasis.   374 
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MATERIALS AND METHODS 375 
Cell lines, siRNAs, lentiviruses, and tumor samples 376 
The human colon cancer cell lines KM12C (poorly metastatic) and KM12SM and KM12L4 377 
(highly metastatic) kindly provided by Dr. I. Fidler (MD Anderson Cancer Center, 378 
Houston, TX) were authenticated by short tandem repeat analysis. SW480, SW620, 379 
LIM1215, HT-29, Colo205, and Colo320 human colon cancer cells were purchased from 380 
ATCC and passaged less than 6 months after purchase. Mycoplasma contamination was 381 
regularly excluded.  Cell lines were cultured in DMEM (Invitrogen) containing 10% FCS 382 
(Invitrogen) with antibiotics at 37ºC in a 5% CO2 humidified atmosphere. For transient 383 
transfections, control siRNAs, or two different siRNAs specifically targeting SOSTDC1 384 
(SASI-Hs01_00149385 and SASI-Hs01_00149386) or ALCAM (SASI-Hs01_0021533 and 385 
SASI-Hs01_0021534) (Sigma-Aldrich) were transfected with JetPrime (Polyplus 386 
Transfection). Stable silencing used the GIPZ Lentiviral shRNA Transfection Starter Kit 387 
with DharmaFECT kb (Dharmacon). In brief, KM12L4 cells were infected with lentiviral 388 
particles containing two different shRNAs against SOSTDC1 (#1 RHS4430-200271487-389 
V3LHS_386617, #2 RHS4430-200202272-V2LHS_96631) or an irrelevant shRNA 390 
(control). After 48 h, stable transfectants were selected with 5 μg/mL puromycin (Sigma-391 
Aldrich) for 2 weeks and then maintained in 0.5 µg/mL puromycin. PP2, LY294002, 392 
UO126 and JNK inhibitor II were purchased from Sigma-Aldrich.   393 
Nine sets of human colon cancer paired samples from primary tumor and liver metastasis 394 
and their healthy tissue counterparts were kindly provided by Dr. A. Villanueva (Institut 395 
Català d’Oncologia. Hospital Duran i Reynals). Sample collection was approved by the 396 
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Ethical Review Board of the hospital. For immunohistochemistry, a tissue microarray based 397 
on tissue samples was obtained from the Surgical Pathology Departments of Hospital 398 
Fundación Jiménez Díaz and Hospital Clínico (Madrid) after approval of the Research 399 
Ethics Committee of the hospitals. Written informed consent was provided by all patients. 400 
Production of SOSTDC1 recombinant proteins 401 
SOSTDC1 wild-type (wt) (aa 24–206; full sequence without the signal peptide) and variant 402 
ΔN67-SOSTDC1 (aa 68–206) were obtained by gene synthesis and cloned into pET28a 403 
(Genescript) with a 6×His tag in the C-terminal regions. Both proteins were expressed in 404 
the BL21 E. coli strain for 4 h at 37ºC after induction with 0.8 mM IPTG. Cell pellets were 405 
extracted by sonication in PBS buffer with 1×Complete Protease Inhibitor (Roche), PMSF, 406 
and 1 mM DTT. The soluble lysate was discarded, and the insoluble fraction of the 407 
extraction was solubilized with 6 M guanidinium chloride overnight. The solubilized 408 
proteins were clarified by centrifugation and filtration with 0.45 µm filter. SOSTDC1 and 409 
ΔN67-SOSTDC1 were purified using HisTrap FF Crude 1 mL column, following the 410 
standard on-column refolding protocol provided by the manufacturer (GE Healthcare) in an 411 
AKTA Prime Plus FPLC system. Recombinant SOSTDC1 was used at 10 ng/mL for 5 min 412 
in flow cytometry and actin polymerization assays. 413 
Immunoprecipitation and mass spectrometry 414 
See Supplementary Information 415 
Cell invasion 416 
21 
 
To evaluate the invasive properties of the cancer cells, 6×104 cells were loaded onto 8-mm 417 
pore-size filters coated with 35 μL of Matrigel (BD Biosciences) diluted 1:3 in DMEM in 418 
Transwell plates (Sigma-Aldrich). The lower compartment of the invasion chamber was 419 
filled with DMEM–5% serum or with recombinant SOSTDC1 (10 ng/mL) in serum-free 420 
DMEM. After 48 h, non-invading cells were removed, and cells that had migrated through 421 
the filter were fixed with 4% paraformaldehyde, stained with crystal violet, and counted 422 
under a microscope. 423 
Flow cytometry and actin polymerization assays 424 
For flow cytometry, 2×105 cells previously detached with 2 mM EDTA in PBS were 425 
incubated with different antibodies (10 µg/mL) in presence of human gamma globulin (20 426 
µg/mL) in PBS for 30 min at 4ºC. After washing, cells were incubated with Alexa-Fluor 427 
488 conjugated secondary antibodies (Thermo Fisher Scientific). Fluorescence was 428 
analyzed in a Coulter Epics XL cytofluorometer. At least 10,000 events per sample were 429 
acquired, and cells were identified on the basis of their specific forward and side light-430 
scattering properties. For actin polymerization assays, cells were fixed with 7.4% 431 
formaldehyde, permeabilized with 1 mg/mL lysophosphatidylcholine, and stained with 1 432 
μg/mL FITC-Phalloidin (Sigma-Aldrich). After washing, cells were analyzed as above. 433 
Immunohistochemistry 434 
Immunohistochemistry staining was carried out as previously described 46. Anti-SOSTDC1 435 
(Abcam) was used at 1:100 dilution and anti-ALCAM (R&D systems) at 1:50 dilution. 436 
In silico analyses of SOSTDC1 sequence, structure and ALCAM expression 437 
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See Supplementary Information 438 
Metastasis experiments in nude mice 439 
Mice experiments were approved by the ethics committee of Consejo Superior de 440 
Investigaciones Científicas and the Community of Madrid (PROEX 252/15). Swiss nude 441 
mice (Charles River; n = 6 per condition) were inoculated in the spleen with 5×105 442 
KM12L4 cells in 25 μL PBS. Mice were inspected daily for signs of disease, such as 443 
abdominal distension, locomotive deficit, or tumor detectable by palpation. When any such 444 
sign was visible, mice were euthanized, analyzed by necropsy, and inspected for liver 445 
metastasis. 446 
Statistical analysis 447 
Data with Gaussian distribution were analyzed by one-way ANOVA followed by Tukey-448 
Kramer multiple comparison test. Histograms showed the average of the assessed value, 449 
whereas the error bars showed the standard deviation. Number of patients with metastasis 450 
was assessed by chi-square test. Protein expressions in primary tumor and metastasis were 451 
analyzed with Wilcoxon matched pairs test. Survival curves were plotted using a Kaplan–452 
Meier analysis and compared with the log-rank test. The minimum acceptable level of 453 
significance in all tests was P < 0.05.  454 
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Legends to the figures 652 
Figure 1. SOSTDC1 is overexpressed in colorectal cancer metastasis. A, Western blot 653 
analysis of distinct colorectal cancer cell lines (as indicated) of SOSTDC1 in the lysate or 654 
media (secreted) (top) and quantification (bottom); anti–α-tubulin was used as loading 655 
control. B, Left, Western blot analysis of SOSTDC1 expression in normal colon (C), 656 
primary tumor (T), normal liver (L), or liver metastasis (M) from colorectal cancer patients; 657 
anti-RhoGDI was used as loading control. Right, band quantification with averages + 658 
standard errors are shown. SOSTDC1 expression was significantly enhanced in liver 659 
metastasis as compared to normal liver or primary tumor (*P < 0.05). C, Left, 660 
quantification of immunohistochemical analysis of SOSTDC1 in colon cancer samples of 661 
paired colon and liver tissues from the same patients; right, representative images. 662 
SOSTDC1 was significantly increased in liver metastasis as compared to primary tumor 663 
(*P < 0.05). 664 
Figure 2. SOSTDC1 promotes cell invasion and activation of signaling pathways. A, 665 
Western blot verification of knockdown of SOSTDC1 in SW620, KM12SM, or  KM12L4 666 
cells, after cells were transfected with siRNAs or shRNA against SOSTDC1 or a control, as 667 
indicated; anti-RhoGDI was used as a loading control. B, C, Invasion assays in Matrigel of 668 
the indicated transfected cells (B) or in the presence of control or anti-SOSTDC1 antibodies 669 
(C). D, Western blot analysis of signaling pathways in SOSTDC1-silenced cells using the 670 
indicated antibodies; anti-RhoGDI was used as a loading control. E, Invasion assays of the 671 
indicated cells towards SOSTDC1 (10 ng/ml) in the presence of different inhibitors 672 
(bottom). Cell invasion was significantly inhibited by SOSTDC1 silencing or anti-673 
SOSTDC1 antibodies (*P < 0.05; **P < 0.01; ***P < 0.001). 674 
Figure 3. SOSTDC1 inhibits BMP4 to maintain expression of stem cell transcription 675 
factors. A, A, Invasion assays of the SOSTDC1-silenced or control KM12L4 cells towards 676 
SOSTDC1 (10 ng/ml) in the presence of different BMP4 concentrations. SOSTDC1-677 
mediated induction of invasive cells was reduced by BMP4 **P < 0.01; ***P < 0.001. B, 678 
Semi-quantitative RT-PCR analysis of the indicated BMP receptors in the metastatic 679 
colorectal cancer cell lines (top left); GAPDH was amplified as loading control. Western 680 
blot analysis of the cell lines silenced or not for SOSTDC1 and treated with different 681 
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concentrations of BMP4; phospho-SMAD5 and total SMAD5 were detected.  C, Colony 682 
formation assays of KM12SM cells in the presence of SOSTDC1 +/– BMP4 at the 683 
indicated concentrations. D, Relative expression of indicated genes after Q-PCR from 684 
SOSTDC1-silenced or control KM12L4 cells +/– BMP4. SOSTDC1-silenced cells treated 685 
with BMP4 (10 ng/mL) showed a significant reduction of the indicated genes or increase in 686 
the mRNA expression levels. **P < 0.01; ***P < 0.001.  687 
Figure 4. SOSTDC1 interacts with ALCAM using a CD6-like motif. A, B, SW620 cell 688 
lysates were immunoprecipitated using anti-SOSTDC1 or control antibodies.  After 689 
SOSTDC1 immunoprecipitation, trypsin-digested immunoprecipitate peptides were 690 
analyzed by nanoLC-MS/MS (A) and identified protein were verified by Western blot (B). 691 
C, Sequence comparison of ALCAM-binding motifs in CD6 and SOSTDC1. D, In silico 692 
model of SOSTDC1 showing the location of ALCAM-binding sequences. E, Confocal 693 
microscopy of SW620 cells showing co-localization of ALCAM and SOSTDC1 in the cell 694 
membrane. F, Western blot verifying the knockdown of ALCAM expression in lysates 695 
from SW620 or KM12SM cells transfected with ALCAM or control siRNAs. G, Flow 696 
cytometry assays to detect the surface expression of SOSTDC1 and ALCAM in cell 697 
transfectants; the mean fluorescence intensity for each marker is shown. 698 
Figure 5. Truncation of SOSTDC1 N-terminus inhibits ALCAM-mediated migration 699 
and invasion. A–C, SW620 or KM12SM cells were treated with SOSTDC1 or ΔN67-700 
SOSTDC1 (10 ng/ml) and analyzed by flow cytometry to detect SOSTDC1 binding (A), 701 
invasion assays through Matrigel towards SOSTDC1 or ΔN67-SOSTDC1 (B), and actin 702 
polymerization assays (C). SOSTDC1 significantly increased, and ΔN67-SOSTDC1 703 
significantly decreased, SOSTDC1 detection in cell surface, cell invasion, and F-actin 704 
content. *P < 0.05; **P < 0.01; ***P < 0.001. D, Western blot analysis of the indicated 705 
cells lines exposed to SOSTDC or ΔN67-SOSTDC1 for the indicated times; the antibodies 706 
used to detect signaling pathways are indicated. 707 
Figure 6. ALCAM regulates cell invasion and actin polymerization in a coordinated 708 
way with SOSTDC1. A, Western blot of lysates from the indicated cell lines transfected 709 
with ALCAM or control siRNA, to verify ALCAM silencing. B, C, Cell invasion assays of 710 
SW620 or KM12SM cells transfected with SOSTDC1 and/or ALCAM siRNAs  were 711 
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analyzed by cell invasion assays (B) and flow cytometry after F-actin polymerization 712 
assays (showing mean intensity fluorescence) (C) *P < 0.05. C, D, Western blots using the 713 
indicated antibodies of lysates from SW620 and KM12SM cells transfected with ALCAM 714 
or control siRNA and not treated (C) or treated with SOSTDC1 (10 ng/ml) (D). E, Western 715 
blot of anti-ALCAM or control antibody immunoprecipitates from SW620 cell lysates, 716 
using the indicated antibodies. F, Immunohistochemistry of ALCAM in colon cancer 717 
samples of paired primary tumors and liver metastasis from the same patients. 718 
Representative images of ALCAM staining intensity are shown. ALCAM expression 719 
significantly increased in liver metastasis compared to primary tumors. *P < 0.05. 720 
Figure 7. SOSTDC1/ALCAM expression correlates with liver metastasis. A functional 721 
model. A, Percentage of patients with liver metastasis according to their expression levels 722 
of SOSTDC1 or ALCAM. High expression of SOSTDC1 or ALCAM increased 723 
significantly the percentage of patients with metastasis. *P < 0.05. B, Kaplan–Meier 724 
survival of mice inoculated in the spleen with KM12L4 cells stably transfected with control 725 
or SOSTDC1 shRNA. Survival time was significantly enhanced in mice inoculated with 726 
SOSTDC1 silenced cells. *P < 0.05. C, Quantification of liver metastasis volume from the 727 
inoculated mice of (B); averages + standard deviation are shown. Liver colonization 728 
decreased significantly in mice inoculated with SOSTDC1 silenced cells. ***P < 0.001. D,  729 
A functional model of mechanisms involving SOSTDC1 during tumor progression. 730 







